Mari Numata-Nakamura, MD, PhD

Special Interests

Mari Numata-Nakamura has got trained and  practiced medicine as a clinical pulmonologist in Japan. She currently focuses on research investigating the role of pulmonary surfactant in regulating innate immunity in the lung, with special emphasis upon surfactant lipid antagonism of inflammation and viral infection. She discovered the anti-viral properties of the surfactant lipids palmitoyl-oleoyl-Phosphatidylglycerol (POPG) and phosphatidylinositol (PI). The long-term goals of her research are to bring basic research observations to treatment of patients.

Education

Education

Yamagata University, School of Medicine, Yamagata, Japan, M.D.

Yokohama City University, Postgraduate School of Medicine, Yokohama, Japan, Ph.D.

Fellowship

Yokohama City University, Postgraduate School of Medicine

Cleveland Clinic Foundation, Department of Pulmonary and Critical Care Medicine, Cleveland, OH

Awards & Recognition

2019: Yamagata University Faculty of Medicine Alumni Association, Zao-kai Award 2018

2011: International Conference on Lung Innate Immunity and Pulmonology at ATS (i-CLIPP 2011), The i-CLIPP

2011: Peter Hansen Award for the Best Poster Presentation

2010: National Jewish Health 2010 Faculty award, Outstanding Scientific Achievement in Basic Research (Nominees)

2010: National Jewish Health 2010 Faculty award, Outstanding Scientific Achievement in Basic Research (Nominees)

2009: American Thoracic Society Travel Award Grant, ATS Assembly of Microbiology, Tuberculosis and Pulmonary   Infections, 2009 International Conference, San Diego, California

2008: American Thoracic Society Travel Award Grant, ATS Assembly on Microbiology, Tuberculosis and Pulmonary Infections, 2008 International Conference, Toronto, Canada

Board Certification

2006: Japanese Society of Allergology

1998: Japanese Society of Respiratory Medicine

1998: Japanese Society of Internal Medicine

Professional Memberships

American Thoracic Society
Japanese Society of Internal Medicine
Japanese Respiratory Society
Japanese Society of Allergology

Patents:

• Surfactant Lipids, Composition Thereof and Uses Thereof. U.S. Patent 8,367,643, issued February 5, 2013.
• Surfactant Lipids, Composition Thereof and Uses Thereof. U.S. Patent 8,796,243, issued August 5, 2014.
• Surfactant Lipids, Composition Thereof and Uses Thereof. U.S. Patent 9,861,649, issued January 9, 2018.
• Surfactant Lipids, Composition Thereof and Uses Thereof. U.S. Patent # 10,532,066, issued January 14, 2020.

Publications

Numata M, Chu HW, Dakhama A, Voelker DR. Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):320-5. PubMed PMID: 20080799; PubMed Central PMCID: PMC2806703.

Voelker DR and Numata M. Phospholipid regulation of innate immunity and respiratory viral infection. J Biol Chem. 2019. 294(12):4282-4289. PubMed PMID:30733339; PubMed Central PMCID: PMC6433062.

Numata M, Sajuthi S, Bochkov YA, Loeffler J, Everman J, Vladar EK, Cooney RA, Reinhardt RL, Liu AH, Seibold MA, Voelker DR. Anionic Pulmonary Surfactant Lipid Treatment Inhibits Rhinovirus A Infection of the Human Airway Epithelium. Viruses. 2023 Mar 14;15(3):747. doi: 10.3390/v15030747. PMID: 36992456; PMCID: PMC10055697.

Numata M, Kandasamy P, Voelker DR. The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids. Immunol Rev. 2023 May 5. doi: 10.1111/imr.13207. PMID: 37144896.

Website Information

Numata-Nakamura Lab